CytoDyn Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Loss per Common Share (Tables)

Loss per Common Share (Tables)

6 Months Ended

Nov. 30, 2023

Loss per Common Share

Schedule of reconciliation of the numerators and denominators of basic and diluted net loss per share


		Three months ended November 30,						Six months ended November 30,
(in thousands, except per share amounts)		2023			2022			2023			2022
Net loss		$	(9,563)		$	(26,495)		$	(21,134)		$	(47,486)
Less: Deemed dividends			—			(1,140)			—			(5,294)
Less: Accrued preferred stock dividends			(368)			(370)			(741)			(756)
Net loss applicable to common stockholders		$	(9,931)		$	(28,005)		$	(21,875)		$	(53,536)
Basic and diluted:
Weighted average common shares outstanding			958,988			813,373			941,191			800,545
Loss per share		$	(0.01)		$	(0.03)		$	(0.02)		$	(0.07)

Schedule of securities excluded from computation of earnings per share


	Three and six months ended November 30,
(in thousands)	2023		2022
Stock options, warrants, and unvested restricted stock units	312,956		204,273
Convertible notes	12,000		12,000
Convertible preferred stock	35,558		32,591